Joint Commission Focus on Medication Compounding Risks

PUBLISHED: Oct 11, 2017
Relevant to: Critical Access Hospitals, Hospitals, Pharmacies

According to The Joint Commission (TJC) contaminated compounded products continue to pose safety risks to patients. TJC assesses sterile compounding processes during its surveys, but TJC is now informing accredited organizations that heightened awareness will be placed on drug compounding during the survey process.

In response to TJCs announcement, accredited organizations will want to review their processes related to medical compounding. Areas to evaluate include ways in which people, products and the environment may contribute to introducing contaminants into the medical compounding process. Also important is reviewing staff competencies to ensure all applicable staff understand the required workflows and precautions that need to be taken when compounding medical products and handling compounded products.

Included with today’s notice are example policies related to medical compounding. Also included is a link to TJC’s recent article about ways to reduce sterile medication compounding risks.

Want to read the full alert and receive alert emails?

Browse Additional Alerts